The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients
Abstract
We reviewed 200 patients with paraneoplastic encephalomyelitis (PEM) and anti-Hu antibodies to show possible clinical differences with respect to previous series, and to identify patient, tumour and treatment-related characteristics associated with neurological disability and survival. The median age of the 200 patients was 63 years (range 28-82 years) and 75% were men. The predominant neurological syndromes were sensory neuropathy (54%), cerebellar ataxia (10%), limbic encephalitis (9%) and multifocal involvement (11%). Sensorimotor neuropathies with predominant motor involvement were observed in only 4% of the patients. Pathological or X-ray evidence of a tumour was obtained in 167 patients (83%) and was a small-cell lung cancer (SCLC) in 74% of those with histological diagnosis. Coexistence of extrathoracic tumours with SCLC was rare (0.5%). Positive Hu immunoreactivity was observed in the extrathoracic tumours of six out of seven patients in whom autopsy or long-term follow-up ruled out a coexisting SCLC. PEM preceded the diagnosis of the tumour in 71% of patients (mean delay +/- SD 6.5 +/- 7.0 months; range 0.1-47 months). In the 24 patients in whom the tumour diagnosis was the initial event, PEM predicted the progression or relapse of the tumour in 87% of them. No tumour was found in 33 patients, including four who had a post-mortem study and four with >5 years of follow-up. In a logistic regression analysis, treatment of the tumour, associated or not with immunotherapy, was an independent predictor of improvement/stabilization of PEM [odds ratio 4.56; 95% confidence interval (CI) 1.62-12.86]. Cox multivariate analysis indicated that the variables independently associated with mortality were: age >60 years [relative risk (RR) 1.49; 95% CI 1.05-2.12], Rankin score at diagnosis >3 (RR 1.60; 95% CI 1.12-2.28), more than one area of the nervous system affected (RR 1.61; 95% CI 1.08-2.40), and absence of treatment (RR 2.56; 95% CI 1.76-3.71). We conclude that, unlike previous series, the majority of our patients were male, and there was a low occurrence of predominantly motor neuropathies and extrathoracic tumours coexisting with SCLC. When the diagnosed extrathoracic tumour expresses Hu antigens, further tests to rule out a coexisting SCLC are probably unnecessary. Finally, the predictors of mortality and PEM evolution found in the study may be important in the design of future therapeutic protocols, and emphasize the importance of early diagnosis and treatment of the underlying tumour.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Turrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., Wagner, H., Aisner, S., & Johnson, D. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400403 · Cited by 1,506
Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography
Pieterman, R. M., van Putten, J. W. G., Meuzelaar, J. J., Mooyaart, E. L., Vaalburg, W., Koëter, G. H., Fidler, V., Pruim, J., & Groen, H. J. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430404 · Cited by 1,111
Dalmau, J., Graus, F., Rosenblum, M. K., & Posner, J. B. (1992) · MEDICINE · doi:10.1097/00005792-199203000-00001 · Cited by 819
Self-citationTHE LAMBERT-EATON MYASTHENIC SYNDROME: A REVIEW OF 50 CASES
O'NEILL, J. H., MURRAY, N. M. F., & NEWSOM-DAVIS, J. (1988) · Brain · doi:10.1093/brain/111.3.577 · Cited by 686
Szabo, A., Dalmau, J., Manley, G., Rosenfeld, M., Wong, E., Henson, J., Posner, J. B., & Furneaux, H. M. (1991) · Cell · doi:10.1016/0092-8674(91)90184-z · Cited by 553
Lucchinetti, C. F., Kimmel, D. W., & Lennon, V. A. (1998) · Neurology · doi:10.1212/wnl.50.3.652 · Cited by 499
Dalmau, J., Furneaux, H. M., Gralla, R. J., Kris, M. G., & Posner, J. B. (1990) · Annals of Neurology · doi:10.1002/ana.410270515 · Cited by 393
PRIMARY SENSORY NEUROPATHY WITH MUSCULAR CHANGES ASSOCIATED WITH CARCINOMA
Denny-Brown, D. (1948) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.11.2.73 · Cited by 380
Graus, F., Dalmou, J., Reñé, R., Tora, M., Malats, N., Verschuuren, J. J., Cardenal, F., Viñolas, N., Garcia del Muro, J., Vadell, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2866 · Cited by 378
Self-citationNeuronal antinuclear antibody in sensory neuronopathy from lung cancer
Graus, F., Cordon-Cardo, C., & Posner, J. B. (1985) · Neurology · doi:10.1212/wnl.35.4.538 · Cited by 368
Self-citationImmunocompromised animal models for the study of antibiotic combinations.
Calandra, T., & Glauser, M. P. (1986) · PubMed · Cited by 287
Furneaux, H. M., Rosenblum, M. K., Dalmau, J., Wong, E., Woodruff, P., Graus, F., & Posner, J. B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006283222604 · Cited by 287
Self-citationLimbic encephalitis and small cell lung cancer. Clinical and immunological features
Alamowitch, S. (1997) · Brain · doi:10.1093/brain/120.6.923 · Cited by 278
Dalmau, J. O., Furneaux, H., Cordon‐Cardo, C., & Posner, J. B. (1992) · PubMed · Cited by 259
Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies
Darnell, R. B., & DeAngelis, L. M. (1993) · The Lancet · doi:10.1016/0140-6736(93)92485-c · Cited by 256
Clinical outcome of patients with anti-Hu–associated encephalomyelitis after treatment of the tumor
Keime-Guibert, F., Graus, F., Broët, P., Reñé, R., Molinuevo, J. L., Ascaso, C., & Delattre, J. Y. (1999) · Neurology · doi:10.1212/wnl.53.8.1719 · Cited by 188
Self-citationGraus, F., Vega, F., Delattre, J. Y., Bonaventura, I., Reñé, R., Arbaiza, D., & Tolosa, E. (1992) · Neurology · doi:10.1212/wnl.42.3.536 · Cited by 186
Self-citation(1995) · Neurology · doi:10.1212/wnl.45.10.1873 · Cited by 169
Utility of anti‐Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy
Molinuevo, J. L., Graus, F., Serrano, C., Reñe, R., Guerrero, A., & Illa, I. (1998) · Annals of Neurology · doi:10.1002/ana.410440620 · Cited by 162
Self-citationCell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies
Benyahia, B., Liblau, R., Merle-B�ral, H., Tourani, J. M., Dalmau, J. O., & Delattre, J. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199902)45:2<162::aid-ana5>3.0.co;2-r · Cited by 158
Wyburn-Mason, R. (1969) · BMJ · doi:10.1136/bmj.3.5665.302-c · Cited by 126
Anti‐Hu‐associated peripheral nerve and muscle microvasculitis
Younger, D. S., Dalmau, J. O., Inghirami, G., Sherman, W. H., & Hays, A. P. (1994) · Neurology · doi:10.1212/wnl.44.1.181-a · Cited by 85
DNA vaccination with HuD inhibits growth of a neuroblastoma in mice.
Carpentier, A. F., Rosenfeld, M. R., Delattre, J., Whalen, R. G., Posner, J. B., & Dalmau, J. O. (1998) · PubMed · Cited by 80
Graus, F., Elkon, K. B., Lloberes, P., et al. (1987) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1987.tb07928.x · Cited by 77
Self-citationSpontaneous neurological improvement in anti-Hu associated encephalomyelitis.
Byrne, T. N., Mason, W. P., Posner, J. B., & Dalmau, J. O. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.3.276 · Cited by 76
Gultekin, S. H., Dalmau, J. O., Graus, Y., Posner, J. B., & Rosenblum, M. K. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199802000-00007 · Cited by 35
Expression of Hel‐N1 and HeL‐N2 in small‐cell lung carcinoma
King, P. H., & Dropcho, E. J. (1996) · Annals of Neurology · doi:10.1002/ana.410390520 · Cited by 28
Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.
van Geel (2001) · Open Repository and Bibliography (University of Luxembourg) · doi:10.1002/1531-8249(20010201)49:2 · Cited by 7
Cited by
Paraneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
Dalmau, J., Tüzün, E., Wu, H., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M., Shimazaki, H., Koide, R., King, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21050 · Cited by 2,492
Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis
Dalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R., & Balice-Gordon, R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70253-2 · Cited by 2,435
Recommended diagnostic criteria for paraneoplastic neurological syndromes
Graus, F. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034447 · Cited by 1,610
Self-citationIrani, S. R., Alexander, S., Waters, P., Kleopa, K. A., Pettingill, P., Zuliani, L., Peles, E., Buckley, C., Lang, B., & Vincent, A. (2010) · Brain · doi:10.1093/brain/awq213 · Cited by 1,359
Paraneoplastic Syndromes Involving the Nervous System
Darnell, R. B., & Posner, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023009 · Cited by 1,062
Metadata
- Authors
- Graus, F.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-06-01
- Volume
- 124
- Issue
- 6
- Pages
- 1138-1148
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2124472369
- Cited by
- 897
- References
- 30
- FWCI
- 18.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.